Incidence of Audiological Adverse Effects Induced by COVID-19 Vaccines: A **Preliminary Study**

Ear, Nose & Throat Journal 2024, Vol. 103(4) 208-210 © The Author(s) 2021 Article reuse guidelines: sagepub.com/journals-permissions DOI: 10.1177/01455613211048975 journals.sagepub.com/home/ear (\$)SAGE

Andrea Ciorba, MD, PhD¹^o, Chiara Bianchini, MD PhD¹, Alberto Caranti, MD¹, Piotr H. Skarzyński, MD PhD^{2,3,4}, Stefano Pelucchi, MD¹, and Stavros Hatzopoulos, PhD¹

Keywords

Audiology, COVID-19 vaccines, adverse effects

Dear Editor

Since the COVID-19 pandemic outbreak in the latter months of 2019, physicians and researchers have rushed to develop effective and safe vaccinal procedures as quickly as possible. Without any doubt, vaccination is the most effective strategy against the spread of the COVID-19 infection. With an unprecedented acceleration in industrial production times, the combination of global scientific and medical efforts yielded numerous vaccination strategies. However, a number of adverse events have been reported for the Pfizer, Moderna, and AstraZeneca vaccines, which are considered the major players in the global vaccination protocols.

The objective of this paper is an initial assessment on the reported post-vaccination adverse effects, involving the auditory and vestibular system. Published on-line data were consulted from two databases: (i) The Italian Drug Agency (Agenzia Italiana del Farmaco—AIFA)¹ and (ii) the Medicines and Healthcare Products Regulatory Agency (MHRA) of the United Kingdom.² AIFA strongly recommends that the adverse effects cited in the database should be considered as reports of "suspected" adverse reactions in relation to the COVID-19 vaccination. In this context, the AIFA and the MHRA data represent only a warning of a possible correlation between the vaccination and the reported symptoms. The available information does not constitute clear evidence for a cause-and-effect relationship, between a vaccine and the reported adverse effects.

The Italian AIFA database was updated on June 26, 2021; for a total of 49 512 799 doses administrated, a total of 76 208 adverse reactions have been reported with 246 391 different symptoms. The MHRA database was updated on July 14, 2021: For 79 564 768 doses administrated, 323 967 adverse reactions were reported with 1 080 156 different symptoms.

The incidence of adverse reactions reported is .15% for the AIFA and .41% for the MHRA data. The information is summarized in Table 1.

Among the symptoms reported, only selected audiovestibular disorders were considered (including hearing loss, tinnitus, dizziness, middle ear diseases, external ear diseases, and other) both from Italian and UK's reports. The category "other" included Eustachian tube disorders, hyperacusia, and inner ear inflammation. The reported symptoms were categorized into these six sub-groups, named Dizziness, Tinnitus, Hearing Loss, Middle Ear Diseases, External Ear Diseases, and Other, for each of the three different vaccines (Pfizer, Moderna, and AstraZeneca) in Italy and in the UK.

The following observations can be made on the available data: overall, different patterns emerged from the two databases. For the Italian data, most complaints were (in terms of decreasing significance) in the areas of Vertigo and Dizziness (.96%), Tinnitus (.11%), and Other (.07%). For the UK data, most complaints were in the areas of Tinnitus (.47%), Vertigo and Dizziness (.30%), and External Ear Disorders (.29%). For the areas of Tinnitus and Vertigo, the complaints per vaccine and per country are not consistent. For example, the Italian

¹Department of ENT & Audiology, University of Ferrara, Ferrara, Italy ²Institute of Sensory Organs, Kajetany, Poland

³Institute of Physiology and Pathology of Hearing, Warsaw, Poland ⁴Department of Heart Failure and Cardiac Rehabilitation, Medical University of Warsaw, Warsaw, Poland

Corresponding Author:

Andrea Ciorba, MD, PhD, Department of ENT & Audiology, University Hospital of Ferrara, Via A. Moro 8 (Cona), Ferrara, Ferrara 44100, Italy. Email: andrea.ciorba@unife.it



Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).

database indicates that for the Vertigo complaints, most of the subjects were inoculated with the Pfizer vaccine. The corresponding data from the UK indicate that the majority of complaints originated from subjects inoculated with the AstraZeneca vaccine. Interestingly, the number of reports from AstraZeneca vaccinated subjects in Italy is much less that the Pfizer ones (18 827 vs 52 604). These numbers suggest that the data available are directly influenced by the unequal number of doses of the delivered vaccines to the target populations and that additional considerations per type of vaccine are not possible at this stage. Unfortunately, since the data refer to adverse postvaccination symptoms and not to a single disease (ie, Meniere's disease or sudden sensorineural hearing loss), it is not possible to compare this sort of data with the established incidence of audiological and vestibular disorders in the Italian and UK populations. Furthermore, since the reported adverse symptoms refer only to a

part of the population (due to various national vaccination policies), it is not possible in this moment of time, to confront the reported adverse effects with the statistical indices established in the literature. Additionally, with the available data, it is not possible to identify the precise locus (and the systems involved) of the side effects reported, since Vertigo, Dizziness, and Tinnitus could have contributing causes outside the Auditory/Vestibular system. There is current research indicating the spectrum of possible factors accounting for the differences in the reported adverse effects (besides the vaccination type), such as age or blood type, but these are still under investigation.³The analytical data per database and audiological subgroup are presented in Table 2.

A closing note on the topic, despite the importance of the vaccination adverse effects on the various human systems, the available literature in the area of hearing and balance is rather poor. The available studies refer to preliminary pilot observation

Table 1. Incidence of Adverse Reactions Reported by MHRA and AIFA.

| taly—AIFA | | | | | | | | | | | | |
|----------------------------|---------|-------|----------|------|-----------------|------|-------------------------|------|---------------------------|------|-------|------|
| | Vertigo | | Tinnitus | | Hearing Loss | | Middle Ear Disorders | | External Ear Disorders | | Other | |
| Comirnaty (Pfizer) | 1406 | .84% | 153 | .09% | 71 | .04% | 2 | .00% | 147 | .09% | 160 | .10% |
| Spikevax (Moderna) | 90 | .80% | 12 | .10% | 10 | .09% | 0 | .00% | 0 | .00% | I | .00% |
| Vaxzevria (AstraZeneca) | 885 | 1.33% | 113 | .17% | 25 | .04% | 0 | .00% | 12 | .02% | П | .02% |
| United Kingdom—MH | RA | | | | | | | | | | | |
| | Vertigo | | Tinnitus | | Hearing loss | | Middle ear disorders | | External ear disorders | | Other | |
| Comirnaty (Pfizer) | 985 | .38% | 1257 | .49% | 355 | .14% | 6 | .00% | 777 | .30% | 118 | .04% |
| Spikevax (Moderna) | 78 | .26% | 110 | .37% | 24 | .08% | 0 | .00% | 69 | .23% | П | .04% |
| Vaxzevria (AstraZeneca) | 2175 | .27% | 3727 | .47% | 724 | .09% | 6 | .00% | 2265 | .28% | 294 | .04% |

Abbreviations: MHRA, Medicines and Healthcare Products Regulatory Agency; AIFA, Agenzia Italiana del Farmaco.

 Table 2.
 Audio-Vestibular Reported Symptoms Have Been Categorized into These Six Groups (Dizziness, Tinnitus, Hearing Loss, Middle Ear Diseases, External Ear Diseases, and Other).

| | United Kingdom—Medicines and Healthcare Products Regulatory Agency | | | | | | | |
|--|--|------|-------------------------------------|-------------|--|--|--|--|
| Vaccine | Number of Reports | % | Total Symptoms Reported | % | | | | |
| Pfizer/BioNTech | 9 567 | 28.3 | 256 005 | 23.7 | | | | |
| Spikevax (Moderna) | 10 109 | 3.1 | 29 606 | 2.7 73.6 | | | | |
| Oxford University/AstraZeneca | 222 291 | 68.6 | 794 545 | | | | | |
| Total doses administrated = 79 564 768 | Total reports = 323 967 | | Total symptoms reported = 1 080 156 | | | | | |
| Italy—AIFA | | | | | | | | |
| Vaccine | Number of reports | % | Total symptoms reported | % | | | | |
| Comirnaty (Pfizer) | 52 604 | 69 | 166 294 | 67.6 | | | | |
| Spikevax (Moderna) | 3947 | 5.2 | 63 | 4.5 | | | | |
| Vaxzevria (AstraZeneca) | 18 827 | 24.7 | 66 526 | 27 | | | | |
| COVID-19 Vaccine Janssen | 816 | 1.1 | 2408 | 0.9 | | | | |
| Total doses administrated = 49 512 799 | Total reports = 76 208 | | Total symptoms reported = 246 391 | | | | | |

attempts on small datasets of subjects. For example, in a recent retrospective study, Wichova et al⁴ presented a cohort of 30 patients affected by otologic symptoms shortly after COVID-19 vaccination but without any evidence of a real correlation. Formeister et al, in a cross-sectional study⁵ evaluating the data by the American CDC Vaccine Adverse Events Reporting System, attempted to establish a relationship between the incidence of sudden sensorineural hearing loss (SSHL) in those vaccinated against the COVID-19 and those non-vaccinated; they reported a similar incidence of SSHL in both sub-groups.

In conclusion, we would like to remark that according to the AIFA recommendation, the available data should be considered as "reported adverse effects" and they do not offer evidence for a real clinical correlation between the symptoms reported and the COVID-19 vaccine mechanisms. Nevertheless, the fact that numerous adverse effects have been reported should be an initiative to investigate in more detail future cases reporting various adverse symptoms. Even a randomized protocol (ie, not including all reported cases, a limit imposed by the available economic resources) would benefit the knowledge which can be acquired on the true performance of these vaccines, in the populations under COVID-19 health surveillance.

ORCID iD

Andrea Ciorba D https://orcid.org/0000-0003-3455-2295

References

- AIFA. https://www.aifa.gov.it/web/guest/farmacovigilanza-vaccinicovid-19
- MHRA. https://www.gov.uk/government/collections/mhra-guidanceon-coronavirus-covid-19#vaccines-and-vaccine-safety
- Calzetta L, Ritondo BL, Coppola A, Matera MG, Di Daniele N, Rogliani P. Factors influencing the efficacy of covid-19 vaccines: a quantitative synthesis of phase III trials. *Vaccines*. 2021;9(4):341.
- Wichova H, Miller ME, Derebery MJ. Otologic manifestations after COVID-19 vaccination: the house ear clinic experience. *Otol Neurotol.* 2021;42(9):e1213-e1218. doi:10.1097/MAO. 000000000003275.
- Formeister EJ, Chien W, Agrawal Y, Carey JP, Stewart CM, Sun DQ. Preliminary analysis of association between covid-19 vaccination and sudden hearing loss using us centers for disease control and prevention vaccine adverse events reporting system data. *JAMA Otolaryngology-Head & Neck Surgery*. 2021;147(7): 674-676. doi:10.1001/jamaoto.2021.0869.